Back
Speaker illustration

Doctor Tomoyuki Nagai

Kyoto Prefectural University of Medicine, Kyoto (Japan)

Member of:

European Society of Cardiology

Presentations

Efficacy and safety of prolonged rivaroxaban treatment for high-bleeding risk cancer patients with acute low-risk pulmonary embolism: a post-hoc subgroup analysis of the ONCO PE trial

Event: ESC Congress 2025

Topic: Venous Thromboembolism

Session: Pulmonary embolism: general

Access
Like
Thumbnail

Efficacy and safety of long-term edoxaban treatment for low body weight cancer patients with isolated distal deep vein thrombosis: a post-hoc subgroup analysis of the ONCO DVT study

Event: ESC Congress 2024

Topic: Venous Thromboembolism

Session: Pearls of acute pulmonary embolism

Access
Like
Thumbnail

Management of doxorubicin-induced cardiomyopathy as the adverse event of chemotherapy in acute critical decompensated heart failure: a case report.

Event: ESC Congress 2022

Topic: Cardio-Oncology

Session: Cardio-oncology – Cancer treatment and cardiovascular toxicity

Access
Like
Thumbnail

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources